Hyperuricemia: Clinical Trials

26 trials for Hyperuricemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 completed. 26 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 126Completed 26
Phase 22Completed 2

Follow Hyperuricemia: new trials by email Literature Review of Hyperuricemia trials Research Report on Hyperuricemia

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval
repaglinide; midazolam; SHR4640, repaglinide; midazolam; SHR4640; SHR4640 placebo, repaglinide; midazolam; SHR4640 placebo - Gout and Hyperuricemia
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.242024-01-042024-03-06
Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects
SHR4640 - Hyperuricemia
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.342023-12-132024-01-23
Effect of Tigulixostat on the Pharmacokinetics of Theophylline
Tigulixostat, Theophylline - Gout, Hyperuricemia
Phase 1CompletedLG Chem242023-10-312024-01-03
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia
Phase 1 / Phase 2CompletedUrica Therapeutics Inc.202023-10-042026-06-10
Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
SHR4640 - Hyperuricemia
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.162023-08-072024-07-11
SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects
SAP-001, Placebo - Gout, Hyperuricemia
Phase 1CompletedShanton Pharma Co., Ltd.702023-05-292024-11-12
A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels
PRX-115, Placebo - Gout
Phase 1CompletedProtalix642023-03-232025-02-11
A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia
SIBP-R002, Dexamethasone or Methyl prednisolone, Diphenhydramine - Asymptomatic Hyperuricemia
Phase 1CompletedShanghai Institute Of Biological Products452022-04-112023-12-27
Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets
Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal, Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state - Hyperuricemia, Gout
Phase 1CompletedAllena Pharmaceuticals122022-01-112023-01-23
Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults
LC350189 Tablet, LC350189 Capsule - Gout, Hyperuricemia
Phase 1CompletedLG Chem232021-07-312022-01-06
Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
ALLN-346, Placebo - Hyperuricemia, Gout
Phase 1CompletedAllena Pharmaceuticals182021-04-212021-07-01
A Safety and Tolerability Study of FCN-207 in Healthy Volunteers
Placebo, fasted vs. high-fat meal - Hyperuricemia
Phase 1CompletedFochon Pharmaceuticals, Ltd.1322020-11-112024-08-05
ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers
ALLN-346, Placebo - Hyperuricemia
Phase 1CompletedAllena Pharmaceuticals242020-09-022021-07-23
Mass Balance Study of [14C]LC350189 in Healthy Volunteers
[14C] LC350189 - Gout, Hyperuricemia
Phase 1CompletedLG Chem62020-02-262020-06-26
The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug - Gout, Hyperuricemia
Phase 1CompletedLG Chem242020-01-222020-06-26
Renal PK Study of LC350189
LC350189 200 mg - Gout, Hyperuricemia
Phase 1CompletedLG Chem372019-11-192020-09-21
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
Xanthine Oxidase Inhibitor - Gout, Hyperuricemia
Phase 1CompletedLG Chem242019-11-052020-06-26
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
ABP-671, Placebo - Hyperuricemia, Gout
Phase 1CompletedAtom Therapeutics Co., Ltd272019-09-052020-02-12
D-0120 Safety and PK/PD Study in China
D-0120 - Hyperuricemia or Gout
Phase 1 / Phase 2CompletedInventisBio Co., Ltd522019-04-182022-05-06
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects
ABP-671, Placebo - Gout, Hyperuricemia
Phase 1CompletedAtom Therapeutics Co., Ltd322018-10-172020-07-29

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Gout (22)

Broader conditions

Pathologic Processes (26)  ·  Pathological Conditions, Signs and Symptoms (26)  ·  Arthritis (22)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (22)  ·  Crystal Arthropathies (22)  ·  Genetic Diseases, Inborn (22)  ·  Joint Diseases (22)  ·  Metabolic Diseases (22)  ·  Metabolism, Inborn Errors (22)  ·  Musculoskeletal Diseases (22)  ·  Nutritional and Metabolic Diseases (22)  ·  Purine-Pyrimidine Metabolism, Inborn Errors (22)  ·  Rheumatic Diseases (22)

Interventions

ruzinurad (6)  ·  Allopurinol (1)  ·  Anti-Inflammatory Agents, Non-Steroidal (1)  ·  Dexamethasone (1)  ·  Diphenhydramine (1)  ·  Midazolam (1)  ·  Naproxen (1)  ·  Theophylline (1)  ·  dotinurad (1)  ·  repaglinide (1)

Sponsors

LG Chem (6)  ·  Jiangsu HengRui Medicine Co., Ltd. (5)  ·  Allena Pharmaceuticals (3)  ·  Atom Therapeutics Co., Ltd (2)  ·  Shanton Pharma Co., Ltd. (2)  ·  Atridia Pty Ltd. (1)  ·  Fochon Pharmaceuticals, Ltd. (1)  ·  InventisBio Co., Ltd (1)  ·  LG Life Sciences (1)  ·  Protalix (1)  ·  SK Chemicals Co., Ltd. (1)  ·  Shanghai Institute Of Biological Products (1)  ·  Urica Therapeutics Inc. (1)

Countries

United States (12)  ·  China (9)  ·  South Korea (2)  ·  Australia (1)  ·  New Zealand (1)  ·  United Kingdom (1)

Top investigators

Christine Tosone (1)  ·  Christine Tosone, MS (1)  ·  Christine Tosone, MS, RAC (1)  ·  Danielle Armas, M.D. (1)  ·  Danielle Armas, MD (1)  ·  Huan Zhou (1)  ·  Ji-Young Park, M.D., Ph.D. (1)  ·  John M Hill, MD (1)  ·  Kyung Sang Yu, MD, PhD (1)  ·  Li Li (1)  ·  Mark Marshall, Dr. (1)  ·  Melanie Fein (1)  ·  Peter Winkle (1)  ·  Sam Salman, B.Sc.BMBS (1)

Results publications

PMID 39530130